Sökning: onr:"swepub:oai:DiVA.org:liu-150237"
> (2018) >
Perspectives for pe...
Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis
-
- Lange, C. (författare)
- Karolinska Institutet,Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany; Karolinska Inst, Sweden
-
- Alghamdi, W. A. (författare)
- Univ Florida, FL USA
-
- Al-Shaer, M. H. (författare)
- Univ Florida, FL USA,German Ctr Infect Res DZIF, Germany; Res Ctr Borstel, Germany,Natl Reference Ctr Mycobacteria, Germany
-
visa fler...
-
- Brighenti, S. (författare)
- Karolinska Institutet,Karolinska Univ Hosp Huddinge, Sweden
-
- Diacon, A. H. (författare)
- Task Appl Sci, South Africa; Stellenbosch Univ, South Africa
-
- DiNardo, A. R. (författare)
- Baylor Coll Med, TX 77030 USA
-
- Grobbel, H. P. (författare)
- Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany
-
- Groschel, M. I. (författare)
- Univ Groningen, Netherlands; Natl Reference Ctr Mycobacteria, Germany
-
- von Groote-Bidlingmaier, F. (författare)
- Task Appl Sci, South Africa
-
- Hauptmann, M. (författare)
- German Ctr Infect Res DZIF, Germany; Res Ctr Borstel, Germany
-
- Heyckendorf, J. (författare)
- Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany
-
- Kohler, N. (författare)
- Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany
-
- Kohl, T. A. (författare)
- Natl Reference Ctr Mycobacteria, Germany,Bernhard Nocht Inst Trop Med, Germany
-
- Merker, M. (författare)
- Natl Reference Ctr Mycobacteria, Germany,Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany
-
- Niemann, S. (författare)
- German Ctr Infect Res DZIF, Germany; Natl Reference Ctr Mycobacteria, Germany
-
- Peloquin, C. A. (författare)
- Univ Florida, FL USA
-
- Reimann, M. (författare)
- Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany
-
- Schaible, U. E. (författare)
- German Ctr Infect Res DZIF, Germany; Res Ctr Borstel, Germany; Univ Lubeck, Germany; LRA INFECTIONS 21, Germany
-
- Schaub, D. (författare)
- Res Ctr Borstel, Germany; German Ctr Infect Res DZIF, Germany; Univ Lubeck, Germany
-
- Schleusener, V. (författare)
- Natl Reference Ctr Mycobacteria, Germany
-
- Thye, T. (författare)
- Bernhard Nocht Inst Trop Med, Germany
-
- Schön, Thomas (författare)
- Linköpings universitet,Avdelningen för mikrobiologi och molekylär medicin,Medicinska fakulteten,Department of Clinical Microbiology and Infectious Diseases, Kalmar County Hospital
-
visa färre...
-
(creator_code:org_t)
- 2018-07-11
- 2018
- Engelska.
-
Ingår i: Journal of Internal Medicine. - : WILEY. - 0954-6820 .- 1365-2796. ; 284:2, s. 163-188
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Allmänmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- General Practice (hsv//eng)
Nyckelord
- individualized medicine; MDR-TB; personalized medicine; XDR-TB
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Lange, C.
-
Alghamdi, W. A.
-
Al-Shaer, M. H.
-
Brighenti, S.
-
Diacon, A. H.
-
DiNardo, A. R.
-
visa fler...
-
Grobbel, H. P.
-
Groschel, M. I.
-
von Groote-Bidli ...
-
Hauptmann, M.
-
Heyckendorf, J.
-
Kohler, N.
-
Kohl, T. A.
-
Merker, M.
-
Niemann, S.
-
Peloquin, C. A.
-
Reimann, M.
-
Schaible, U. E.
-
Schaub, D.
-
Schleusener, V.
-
Thye, T.
-
Schön, Thomas
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Allmänmedicin
- Artiklar i publikationen
-
Journal of Inter ...
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet